Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Search
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Boehringer Ingelheim announces appointments Board of Managing Directors
Boehringer Ingelheim announces appointments Board of Managing Directors
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Valerie Nock
My career challengeFunctional Areas at Boehringer Ingelheim
Careers beyond borders
Careers beyond borders
A life in a day: the reality of living with lung cancer
Within the initiative “A life in a day”, Anna-Maria spent 24 hours in the shoes of a lung cancer patient to better understand the patient experience.
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Maria Weber
Lead Patient Safety Physician Maria Weber tells us about why she joined Boehringer Ingelheim, and the importance of patient centricity in everything she does.
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
Tackling supply chain challenges for a country at war
We are there for our patients – even in crisis regions. A supply chain success story with our Ukrainian colleague Tetiana Nagirna from Kyiv.
Cardio-Renal-Metabolic
Cardio-Renal-Metabolic Therapeutic Area
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Cooperation with Google Quantum AI
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets